Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study

Authors :: van Leth, F.
Phanuphak, P.
Ruxrungtham, K.
Baraldi, E.
Miller, S.
Gazzard, B.
Cahn, P.
Lalloo, U.G.
van der Westhuizen, I.P.
Malan, D.R.
Johnson, M.A.
Santos, B.R.
Mulcahy, F.
Wood, R.
Levi, G.C.
Reboredo, G.
Squires, K.
Cassetti, I.
Petit, D.
Raffi, F.
Katlama, C.
Murphy, R.L.
Horban, A.
Dam, J.P.
Hassink, E.
van Leeuwen, R.
Robinson, P.
Wit, F.W.
Lange, J.M.A.
Source :: The Lancet. April 17, 2004, Vol. 363 Issue 9417, p1253
Publication Year :: 2004

Subjects :: Nevirapine -- Comparative analysis
Reverse transcriptase inhibitors -- Health aspects
Reverse transcriptase inhibitors -- Research
Antiviral agents -- Comparative analysis
Antiviral agents -- Research

Tools